USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
On Thursday, The Pharma Letter reported that privately-held biotech startup Immunochina had become the latest Chinese venture to attract overseas investment as it raised 50 million renminbi ($7.5 million) in a funding round. 24 November 2017
While many in the UK life sciences sector have looked on with concern as Brexit-backing Conservatives have pushed the nation towards exiting the European Union (EU) without even agreeing a deal with the trade bloc, the government’s promises over the past year for funding for science and health have been widely welcomed by the industry. 22 November 2017
French biotech start-up Step Pharma yesterday announced the closing of a Series A financing totalling 14.5 million euros ($16.4 million), with the proceeds to be used to support advancement of first-in-class immunomodulators for autoimmune diseases towards clinical studies. 22 November 2017
Germany-headquartered Fresenius Kabi, a company specializing in medicines and technologies for infusion, transfusion and clinical nutrition, will expand its manufacturing operations North Carolina, USA. 22 November 2017
Acorda Therapeutics, which last week suffered a significant setback with its Phase III program of Parkinson’s disease drug tozadenant, on Friday announced a $40 million royalty monetization with HealthCare Royalty Partners (HCR) and a $13 million royalty monetization with Denmark’s Lundbeck. 18 November 2017
Thomas Busby and Oded Ben-Joseph, from investment bank Outcome Capital, look at some of the hurdles to accessing venture capital, and how companies can overcome them. 10 November 2017
The shares of German life sciences group Merck KGaA rose 1.2% to 93.48 euros in early trading, when it released third-quarter 2017 financial results. 9 November 2017
Better-than-expected third-quarter financial results at Regeneron Pharmaceuticals sent its share price up by 1%, to $408.75, after four hours of trading on Wednesday. 8 November 2017
Danish CNS specialist saw its shares drop 6.07% to 352.00 Danish kroner this morning, as it posted a strong set of financials for the first nine months of 2017. 8 November 2017
Canada’s Valeant Pharmaceuticals International, which has been shedding former acquisitions like confetti in order to reduce its debt burden, today reported better-than-expected third-quarter 2017 financials. 7 November 2017
The sales figures and stock value of Catalan drugmaker Almirall have taken a pummeling this year, and the latest results showed that the third quarter had been another tough one for Spain’s biggest pharma company. 6 November 2017
Netherlands-incorporated generics major Mylan saw its shares rise 0.9% to $36.40 in late-morning trading, have hit a $36.92 pre-market after posting third-quarter 2017 financials that came in below analysts’ forecasts. 6 November 2017
The first job of Kåre Schultz, the new president chief executive of Teva Pharmaceutical Industries, will be to pick the company off the floor after another disastrous set of financial results and subsequent stock market pounding. 2 November 2017
French pharma major Sanofi today posted third-quarter 2017 financials, which came in slightly below expectations and showing that total sales rose 4.7% to 9.05 billion euros ($10.54 billion). 2 November 2017
Danish diabetes giant Novo Nordisk saw its shares dip this morning, after the company warned that draft legislation in some US states to make pricing more transparent could impact business in its largest market, and forecast only modest growth for the full years 2017 and 2018. 1 November 2017
Pfizer beat Wall Street earnings estimates with its third-quarter results, but no-one was getting too carried away at the US pharma giant or among its investors. 31 October 2017
Shares of USA-based AbbVie (NYSE: ABBV) closed up 2.33% at $91.93 on Friday, having hit a day high of $94.97, after the company post third-quarter 2017 financial results. 28 October 2017
Ireland-headquartered Shire saw its shares close up 1.5% at 3,576.57 pence on Friday, after the company posted third-quarter 2017 earnings that beat expectations. 28 October 2017
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news